EMAIL THIS PAGE TO A FRIEND

BMC immunology

JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.


PMID 28830352

Abstract

We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE. We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4 Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P8759
Pyrogallol Red
C19H12O8S
T6575
TOFA, ≥98% (HPLC)
C19H32O4